| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 95004 |
Percutaneous tests with allergenic extracts, immediate type reaction |
8,823 |
8,326 |
$2.02M |
| 99204 |
Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity |
10,682 |
10,341 |
$1.36M |
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
20,728 |
19,954 |
$1.16M |
| 95165 |
Professional services for the supervision of preparation and provision of antigens for allergen immunotherapy, multiple dose vials |
4,370 |
3,354 |
$1.06M |
| 95117 |
|
46,229 |
19,628 |
$384K |
| 99212 |
Office or other outpatient visit for the evaluation and management of an established patient, straightforward |
11,824 |
9,799 |
$374K |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
11,247 |
9,306 |
$344K |
| 94010 |
|
8,962 |
8,110 |
$215K |
| 95024 |
|
1,192 |
1,135 |
$105K |
| 99203 |
Office or other outpatient visit for the evaluation and management of a new patient, low complexity |
964 |
938 |
$86K |
| 96401 |
|
252 |
226 |
$22K |
| 95044 |
|
25 |
24 |
$7K |
| 96160 |
|
1,868 |
1,703 |
$6K |
| 94060 |
|
125 |
122 |
$5K |
| 95115 |
|
398 |
160 |
$3K |
| 94640 |
Pressurized or nonpressurized inhalation treatment for acute airway obstruction |
127 |
122 |
$1K |
| J7612 |
Levalbuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, concentrated form, 0.5 mg |
81 |
77 |
$42.23 |
| J2357 |
Injection, omalizumab, 5 mg |
8,519 |
7,135 |
$28.14 |
| J3590 |
Unclassified biologics |
1,167 |
862 |
$3.32 |
| J0517 |
Injection, benralizumab, 1 mg |
26 |
25 |
$0.06 |